Medtronic
(NYSE: MDT)
today announced real-world data demonstrating the global consistency of its MiniMed 780G automated insulin delivery system.
The data demonstrates that using the system allows people with diabetes to meet or exceed internationally recommended targets regardless of location. Medtronic says a barrier to automated insulin delivery (AID) adoption and reimbursement in developing and middle-income countries has been a lack of data supporting its performance and cost-effectiveness in those regions. This comes as a result of large disparities in ethnic, cultural and regional representation in clinical and real-world studies.
Medtronic said its successful results support calls to provide AID systems within underserved populations. Data came from more than 67,000 MiniMed 780G users in Europe, the Middle East, Africa, Latin America, Oceania and Asia. The company presented its data at the European Association for the Study of Diabetes (EASD) 59th Annual Meeting in Hamburg, Germany.
Data demonstrated that average glycemic control exceeded internationally recommended targets. The American Diabetes Association recommends 70% time in range between 70-180 mg/dL. Using MiniMed 780G further improves glycemic outcomes and narrows the differences across regions, the company said. This suggests that the system nearly equalizes performance across disparate regions of the world.
Get the full story at our sister site, Drug Delivery Business News.